Home
Notification
Profile
Trending Articles
News
Bookmarked and Liked
History
Creator Center
Settings
Beau Deblieck Fd62
--
Follow
if you like peptides you're going to love when we find the peptide that inhibits the peptide that inhibits INMT so you can produce endogenous DMT
Disclaimer: Includes third-party opinions. No financial advice. May include sponsored content.
See T&Cs.
51
0
Explore the latest crypto news
⚡️ Be a part of the latests discussions in crypto
💬 Interact with your favorite creators
👍 Enjoy content that interests you
Email / Phone number
Sign Up
Login
Relevant Creator
Beau Deblieck Fd62
@Square-Creator-ecd32469e5df8
Follow
Explore More From Creator
attn: $PSYC hodlers. dive deep. weekly jam sesh starts now. eDMT, dev, AI, Amazonian botanicals, and more. https://discord.com/events/898139202594668585/1378030749810167968/1397941390540800000
--
put it in your brain
--
🚨BREAKING: $PSY Holders Vote to Fund Research into Endogenous DMT Biosynthesis 🚨 PsyDAO to partner with leading researchers and institutions Asking❓is there DMT in our bodies? how is it made and broken down? can we dial it up and down? 💊 Vote totals here: https://t.co/KdtFu5lc8E @alieninsect @noonautics @UFHealth
--
* DMT voting ends July 19 at 14:20 MT / 22:20 CET $PSY hodlers take note ... and vote. https://snapshot.box/#/s:psydao.eth/proposal/0x4d58953af32e929b877b01119b621c73d0092a7560f8a130062ec008ad2fe94b/votes
--
DMT entities can't vote on funding DMT research 👾 So $PSY hodlers have to Polls close Friday at 14:20 MDT / 22:20 CEST https://snapshot.box/#/s:psydao.eth/proposal/0x4d58953af32e929b877b01119b621c73d0092a7560f8a130062ec008ad2fe94b
--
Latest News
Bitcoin(BTC) Surpasses 119,000 USDT with a 0.88% Increase in 24 Hours
--
Ethereum(ETH) Surpasses 3,700 USDT with a 3.22% Increase in 24 Hours
--
TRON Inc. Celebrates Nasdaq Rebranding with Justin Sun's Participation
--
Bitmine Immersion Expands ATM Program to $4.5 Billion
--
Stablecoin Supply Expected to Surge Following GENIUS Act Passage
--
View More
Sitemap
Cookie Preferences
Platform T&Cs